- Home
- DTIL vs GUTS Comparison
DTIL vs GUTS Comparison
Compare DTIL & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- GUTS
- Stock Information
- Founded
- DTIL 2006
- GUTS 2010
- Country
- DTIL United States
- GUTS United States
- Employees
- DTIL N/A
- GUTS N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- GUTS
- Sector
- DTIL Health Care
- GUTS
- Exchange
- DTIL Nasdaq
- GUTS NYSE
- Market Cap
- DTIL 51.6M
- GUTS 58.8M
- IPO Year
- DTIL 2019
- GUTS 2024
- Fundamental
- Price
- DTIL $4.83
- GUTS $1.95
- Analyst Decision
- DTIL Strong Buy
- GUTS Buy
- Analyst Count
- DTIL 2
- GUTS 1
- Target Price
- DTIL $47.00
- GUTS $10.00
- AVG Volume (30 Days)
- DTIL 74.8K
- GUTS 253.9K
- Earning Date
- DTIL 05-15-2025
- GUTS 05-13-2025
- Dividend Yield
- DTIL N/A
- GUTS N/A
- EPS Growth
- DTIL N/A
- GUTS N/A
- EPS
- DTIL N/A
- GUTS N/A
- Revenue
- DTIL $51,141,000.00
- GUTS $60,000.00
- Revenue This Year
- DTIL N/A
- GUTS N/A
- Revenue Next Year
- DTIL $30.20
- GUTS N/A
- P/E Ratio
- DTIL N/A
- GUTS N/A
- Revenue Growth
- DTIL N/A
- GUTS N/A
- 52 Week Low
- DTIL $3.61
- GUTS $0.87
- 52 Week High
- DTIL $13.32
- GUTS $7.05
- Technical
- Relative Strength Index (RSI)
- DTIL 46.95
- GUTS 56.42
- Support Level
- DTIL $4.51
- GUTS $1.66
- Resistance Level
- DTIL $5.10
- GUTS $1.97
- Average True Range (ATR)
- DTIL 0.27
- GUTS 0.17
- MACD
- DTIL -0.00
- GUTS -0.00
- Stochastic Oscillator
- DTIL 40.00
- GUTS 49.31
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.